Harbour BioMed is a fast-growing global biotech company with facilities in Rotterdam, Boston and Shanghai. The company is laser-focused on developing both proprietary and in-licensed immunological therapies using their state-of-the-art transgenic mice technology platforms, which it also licenses to other biotechs. CEO Dr. Jingsong Wang discusses the firm’s strategy, its ambitions in China and globally, and its close partnerships with biotechs and research centres around the world.
The talent pool [in China] is growing as foreign-educated scientists and engineers are returning to their home country, initially joining the burgeoning CRO sector and MNCs, and now gradually moving to the local biotech scene. I am one of them!
